Radiomics of Liver Metastases: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Lily Guo and Version 1 by Luca Viganò.

Multidisciplinary management of patients with liver metastases (LM) requires a precision medicine approach, based on adequate profiling of tumor biology and robust biomarkers. Radiomics, defined as the high-throughput identification, analysis, and translational applications of radiological textural features, could fulfill this need. The present review aims to elucidate the contribution of radiomic analyses to the management of patients with LM. We performed a systematic review of the literature through the most relevant databases and web sources. English language original articles published before June 2020 and concerning radiomics of LM extracted from CT, MRI, or PET-CT were considered. Thirty-two papers were identified. Baseline higher entropy and lower homogeneity of LM were associated with better survival and higher chemotherapy response rates. A decrease in entropy and an increase in homogeneity after chemotherapy correlated with radiological tumor response. Entropy and homogeneity were also highly predictive of tumor regression grade. In comparison with RECIST criteria, radiomic features provided an earlier prediction of response to chemotherapy. Lastly, texture analyses could differentiate LM from other liver tumors. The commonest limitations of studies were small sample size, retrospective design, lack of validation datasets, and unavailability of univocal cut-off values of radiomic features. In conclusion, radiomics can potentially contribute to the precision medicine approach to patients with LM, but interdisciplinarity, standardization, and adequate software tools are needed to translate the anticipated potentialities into clinical practice.

  • radiomics
  • texture analysis
  • computer-assisted diagnosis
  • liver metastases
  • gray level matrices
  • response to chemotherapy
  • overall and recurrence-free survival
Please wait, diff process is still running!

References

  1. Massagué, J.; Obenauf, A.C. Metastatic colonization by circulating tumour cells. Nature 2016, 529, 298–306, doi:10.1038/nature17038.
  2. Van Cutsem, E.; Cervantes, A.; Adam, R.; Sobrero, A.; Van Krieken, J.H.; Aderka, D.; Aguilar, E.A.; Bardelli, A.; Benson, A.; Bodoky, G.; et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 2016, 27, 1386–1422, doi:10.1093/annonc/mdw235.
  3. Pavel, M.; Öberg, K.; Falconi, M.; Krenning, E.; Sundin, A.; Perren, A.; Berruti, A. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020, 31, 844–860, doi:10.1016/j.annonc.2020.03.304.
  4. Cardoso, F.; Senkus, E.; Costa, A.; Papadopoulos, E.; Aapro, M.; André, F.; Harbeck, N.; Lopez, B.A.; Barrios, C.; Bergh, J.; et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)dagger. Ann. Oncol. 2018, 29, 1634–1657, doi:10.1093/annonc/mdy192.
  5. Riihimäki, M.; Hemminki, A.; Sundquist, K.; Sundquist, J.; Hemminki, K. Metastatic spread in patients with gastric cancer. Oncotarget 2016, 7, 52307–52316, doi:10.18632/oncotarget.10740.
  6. Loupakis, F.; Cremolini, C.; Masi, G.; Lonardi, S.; Zagonel, V.; Salvatore, L.; Cortesi, E.; Tomasello, G.; Ronzoni, M.; Spadi, R.; et al. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. N. Engl. J. Med. 2014, 371, 1609–1618, doi:10.1056/NEJMoa1403108.
  7. Kopetz, S.; Chang, G.J.; Overman, M.J.; Eng, C.; Sargent, D.J.; Larson, D.W.; Grothey, A.; Vauthey, J.-N.; Nagorney, D.M.; McWilliams, R.R. Improved Survival in Metastatic Colorectal Cancer Is Associated with Adoption of Hepatic Resection and Improved Chemotherapy. J. Clin. Oncol. 2009, 27, 3677–3683, doi:10.1200/JCO.2008.20.5278.
  8. Gruenberger, T.; Bridgewater, J.; Chau, I.; Alfonso, P.G.; Rivoire, M.; Mudan, S.; Lasserre, S.; Hermann, F.; Waterkamp, D.; Adam, R. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: The OLIVIA multinational randomised phase II trial. Ann. Oncol. 2015, 26, 702–708, doi:10.1093/annonc/mdu580.
  9. Brudvik, K.W.; Jones, R.P.; Giuliante, F.; Shindoh, J.; Passot, G.; Chung, M.H.; Song, J.; Li, L.; Dagenborg, V.J.; Fretland, A.A.; et al. RAS Mutation Clinical Risk Score to Predict Survival after Resection of Colorectal Liver Metastases. Ann. Surg. 2019, 269, 120–126, doi:10.1097/SLA.0000000000002319.
  10. Viganò, L.; Russolillo, N.; Ferrero, A.; Langella, S.; Sperti, E.; Capussotti, L. Evolution of Long-Term Outcome of Liver Resection for Colorectal Metastases: Analysis of Actual 5-Year Survival Rates over Two Decades. Ann. Surg. Oncol. 2012, 19, 2035–2044, doi:10.1245/s10434-011-2186-1.
  11. Creasy, J.M.; Sadot, E.; Blumgart, L.H.; Jarnagin, W.R.; D’Angelica, M.I.; Koerkamp, B.G.; Chou, J.F.; Gonen, M.; Kemeny, N.E.; Balachandran, V.P.; et al. Actual 10-year survival after hepatic resection of colorectal liver metastases: What factors preclude cure? Surgery 2018, 163, 1238–1244, doi:10.1016/j.surg.2018.01.004.
  12. Viganò, L.; Procopio, F.; Cimino, M.; Donadon, M.; Gatti, A.; Costa, G.; Del Fabbro, D.; Torzilli, G. Is Tumor Detachment from Vascular Structures Equivalent to R0 Resection in Surgery for Colorectal Liver Metastases? An Observational Cohort. Ann. Surg. Oncol. 2016, 23, 1352–1360, doi:10.1245/s10434-015-5009-y.
  13. Gennaro, N.; Mauri, G.; Varano, G.M.; Monfardini, L.; Pedicini, V.; Poretti, D.; Solbiati, L.A. Thermal Ablations for Colorectal Liver Metastases. Dig. Dis. Interv. 2019, 3, 117–125, doi:10.1055/s-0039-1688724.
  14. Chung, C. Management of neuroendocrine tumors. Am. J. Health Syst. Pharm. 2016, 73, 1729–1744, doi:10.2146/ajhp150373.
  15. Scorsetti, M.; Franceschini, D.; De Rose, F.; Comito, T.; Franzese, C.; Masci, G.; Torrisi, R.; Viganò, L.; Torzilli, G. The role of SBRT in oligometastatic patients with liver metastases from breast cancer. Rep. Pr. Oncol. Radiother. 2017, 22, 163–169, doi:10.1016/j.rpor.2016.07.008.
  16. Andreou, A.; Viganò, L.; Zimmitti, G.; Seehofer, D.; Dreyer, M.; Pascher, A.; Bahra, M.; Schoening, W.; Schmitz, V.; Thuss-Patience, P.C.; et al. Response to Preoperative Chemotherapy Predicts Survival in Patients Undergoing Hepatectomy for Liver Metastases from Gastric and Esophageal Cancer. J. Gastrointest. Surg. 2014, 18, 1974–1986, doi:10.1007/s11605-014-2623-0.
  17. Adam, R.; Pascal, G.; Castaing, D.; Azoulay, D.; Delvart, V.; Paule, B.; Levi, F.; Bismuth, H. Tumor Progression while on Chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann. Surg. 2004, 240, 1052–1064; discussion 1061–1054, doi:10.1097/01.sla.0000145964.08365.01.
  18. Viganò, L.; Capussotti, L.; Barroso, E.; Nuzzo, G.; Laurent, C.; Ijzermans, J.N.M.; Gigot, J.-F.; Figueras, J.; Gruenberger, T.; Mirza, D.F.; et al. Progression while Receiving Preoperative Chemotherapy Should Not Be an Absolute Contraindication to Liver Resection for Colorectal Metastases. Ann. Surg. Oncol. 2012, 19, 2786–2796, doi:10.1245/s10434-012-2382-7.
  19. Brouquet, A.; Blot, C.; Allard, M.A.; Lazure, T.; Sebbagh, M.; Gayet, M.; Lewin, M.; Adam, R.; Penna, C.; Sa Cunha, A.; et al. What is the Prognostic Value of a Discordant Radiologic and Pathologic Response in Patients Undergoing Resection of Colorectal Liver Metastases after Preoperative Chemotherapy? Ann. Surg. Oncol. 2020, doi:10.1245/s10434-020-08284-1.
  20. Viganò, L.; Capussotti, L.; De Rosa, G.; De Saussure, W.O.; Mentha, G.; Rubbia-Brandt, L. Liver Resection for Colorectal Metastases after Chemotherapy: Impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann. Surg. 2013, 258, 731–740; discussion 741–732, doi:10.1097/SLA.0b013e3182a6183e.
  21. Viganò, L.; Darwish, S.S.; Rimassa, L.; Cimino, M.; Carnaghi, C.; Donadon, M.; Procopio, F.; Personeni, N.; Del Fabbro, D.; Santoro, A.; et al. Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? Ann. Surg. Oncol. 2018, 25, 1676–1685, doi:10.1245/s10434-018-6387-8.
  22. Sayagués, J.M.; Corchete, L.A.; Gutiérrez, M.L.; Sarasquete, M.E.; Abad, M.D.M.; Bengoechea, O.; Fermiñán, E.; Anduaga, M.F.; Del Carmen, S.; Iglesias, M.; et al. Genomic characterization of liver metastases from colorectal cancer patients. Oncotarget 2016, 7, 72908–72922, doi:10.18632/oncotarget.12140.
  23. Brudvik, K.W.; Kopetz, S.; Li, L.; Conrad, C.; Aloia, T.A.; Vauthey, J.-N. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br. J. Surg. 2015, 102, 1175–1183, doi:10.1002/bjs.9870.
  24. Gillies, R.J.; Kinahan, P.E.; Hricak, H. Radiomics: Images Are More than Pictures, They Are Data. Radiology 2016, 278, 563–577, doi:10.1148/radiol.2015151169.
  25. Lambin, P.; Rios-Velazquez, E.; Leijenaar, R.; Carvalho, S.; Van Stiphout, R.G.P.M.; Granton, P.; Zegers, C.M.L.; Gillies, R.; Boellard, R.; Dekker, A.; et al. Radiomics: Extracting more information from medical images using advanced feature analysis. Eur. J. Cancer 2012, 48, 441–446, doi:10.1016/j.ejca.2011.11.036.
  26. Sollini, M.; Antunovic, L.; Chiti, A.; Kirienko, M. Towards clinical application of image mining: A systematic review on artificial intelligence and radiomics. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 2656–2672, doi:10.1007/s00259-019-04372-x.
  27. Zwanenburg, A.; Vallières, M.; Abdalah, M.A.; Aerts, H.J.W.L.; Andrearczyk, V.; Apte, A.; Ashrafinia, S.; Bakas, S.; Beukinga, R.J.; Boellaard, R.; et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology 2020, 295, 328–338, doi:10.1148/radiol.2020191145.
  28. Sollini, M.; Cozzi, L.; Antunovic, L.; Chiti, A.; Kirienko, M. PET Radiomics in NSCLC: State of the art and a proposal for harmonization of methodology. Sci. Rep. 2017, 7, 358, doi:10.1038/s41598-017-00426-y.
  29. Thawani, R.; McLane, M.; Beig, N.; Ghose, S.; Prasanna, P.; Velcheti, V.; Madabhushi, A. Radiomics and radiogenomics in lung cancer: A review for the clinician. Lung Cancer 2018, 115, 34–41, doi:10.1016/j.lungcan.2017.10.015.
  30. Wakabayashi, T.; Ouhmich, F.; Gonzalez-Cabrera, C.; Felli, E.; Saviano, A.; Agnus, V.; Savadjiev, P.; Baumert, T.F.; Pessaux, P.; Marescaux, J.; et al. Radiomics in hepatocellular carcinoma: A quantitative review. Hepatol. Int. 2019, 13, 546–559, doi:10.1007/s12072-019-09973-0.
  31. Cozzi, L.; Dinapoli, N.; Fogliata, A.; Hsu, W.-C.; Reggiori, G.; Lobefalo, F.; Kirienko, M.; Sollini, M.; Franceschini, D.; Comito, T.; et al. Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. BMC Cancer 2017, 17, 829, doi:10.1186/s12885-017-3847-7.
  32. Andersen, I.R.; Thorup, K.; Andersen, M.B.; Olesen, R.; Mortensen, F.V.; Nielsen, D.T.; Rasmussen, F. Texture in the monitoring of regorafenib therapy in patients with colorectal liver metastases. Acta Radiol. 2019, 60, 1084–1093, doi:10.1177/0284185118817940.
  33. Dohan, A.; Gallix, B.; Guiu, B.; Le Malicot, K.; Reinhold, C.; Soyer, P.; Bennouna, J.; Ghiringhelli, F.; Barbier, E.; Boige, V.; et al. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut 2020, 69, 531–539, doi:10.1136/gutjnl-2018-316407.
  34. Meyer, M.; Ronald, J.; Vernuccio, F.; Nelson, R.C.; Ramirez-Giraldo, J.C.; Solomon, J.; Patel, B.N.; Samei, E.; Marin, D. Reproducibility of CT Radiomic Features within the Same Patient: Influence of Radiation Dose and CT Reconstruction Settings. Radiology 2019, 293, 583–591, doi:10.1148/radiol.2019190928.
  35. Dercle, L.; Ammari, S.; Bateson, M.; Durand, P.B.; Haspinger, E.; Massard, C.; Jaudet, C.; Varga, A.; Deutsch, E.; Soria, J.-C.; et al. Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence. Sci. Rep. 2017, 7, 7952, doi:10.1038/s41598-017-08310-5.
  36. Ahn, S.J.; Kim, J.H.; Lee, S.M.; Park, S.J.; Han, J.K. CT reconstruction algorithms affect histogram and texture analysis: Evidence for liver parenchyma, focal solid liver lesions, and renal cysts. Eur. Radiol. 2019, 29, 4008–4015, doi:10.1007/s00330-018-5829-9.
  37. Ahn, S.J.; Kim, J.H.; Park, S.J.; Han, J.K. Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis. Eur. J. Radiol. 2016, 85, 1867–1874, doi:10.1016/j.ejrad.2016.08.014.
  38. Beckers, R.; Trebeschi, S.; Maas, M.; Schnerr, R.; Sijmons, J.; Beets, G.; Houwers, J.; Beets-Tan, R.; Lambregts, D.M.J. CT texture analysis in colorectal liver metastases and the surrounding liver parenchyma and its potential as an imaging biomarker of disease aggressiveness, response and survival. Eur. J. Radiol. 2018, 102, 15–21, doi:10.1016/j.ejrad.2018.02.031.
  39. Cheng, J.; Wei, J.; Tong, T.; Sheng, W.; Zhang, Y.; Han, Y.; Gu, D.; Hong, N.; Ye, Y.; Tian, J.; et al. Prediction of Histopathologic Growth Patterns of Colorectal Liver Metastases with a Noninvasive Imaging Method. Ann. Surg. Oncol. 2019, 26, 4587–4598, doi:10.1245/s10434-019-07910-x.
  40. Dercle, L.; Lu, L.; Schwartz, L.H.; Qian, M.; Tejpar, S.; Eggleton, P.; Zhao, B.; Piessevaux, H. Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway. J. Natl. Cancer Inst. 2020, doi:10.1093/jnci/djaa017.
  41. Klaassen, R.; LaRue, R.T.H.M.; Mearadji, B.; Van Der Woude, S.O.; Stoker, J.; Lambin, P.; Van Laarhoven, H.W.M. Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients. PLoS ONE 2018, 13, e0207362, doi:10.1371/journal.pone.0207362.
  42. Li, Y.; Eresen, A.; Shangguan, J.; Yang, J.; Lu, Y.; Chen, D.; Wang, J.; Velichko, Y.; Yaghmai, V.; Zhang, Z. Establishment of a new non-invasive imaging prediction model for liver metastasis in colon cancer. Am J Cancer Res 2019, 9, 2482–2492.
  43. Lubner, M.G.; Stabo, N.; Lubner, S.J.; Del Rio, A.M.; Song, C.; Halberg, R.B.; Pickhardt, P.J. CT textural analysis of hepatic metastatic colorectal cancer: Pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. Abdom. Imaging 2015, 40, 2331–2337, doi:10.1007/s00261-015-0438-4.
  44. Martini, I.; Polici, M.; Zerunian, M.; Panzuto, F.; Rinzivillo, M.; Landolfi, F.; Magi, L.; Caruso, D.; Eid, M.; Annibale, B.; et al. CT texture analysis of liver metastases in PNETs versus NPNETs: Correlation with histopathological findings. Eur. J. Radiol. 2020, 124, 108812, doi:10.1016/j.ejrad.2020.108812.
  45. Rao, S.-X.; Lambregts, D.M.J.; Schnerr, R.S.; Beckers, R.C.; Maas, M.; Albarello, F.; Riedl, R.G.; DeJong, C.H.; Martens, M.H.; Heijnen, L.A.; et al. CT texture analysis in colorectal liver metastases: A better way than size and volume measurements to assess response to chemotherapy? United Eur. Gastroenterol. J. 2016, 4, 257–263, doi:10.1177/2050640615601603.
  46. Ravanelli, M.; Agazzi, G.M.; Tononcelli, E.; Roca, E.; Cabassa, P.; Baiocchi, G.; Berruti, A.; Maroldi, R.; Farina, D. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: A pilot study including comparison with standard chemotherapy. La Radiol. Med. 2019, 124, 877–886, doi:10.1007/s11547-019-01046-4.
  47. Simpson, A.L.; Doussot, A.; Creasy, J.M.; Adams, L.B.; Allen, P.J.; DeMatteo, R.P.; Gönen, M.; Kemeny, N.E.; Kingham, T.P.; Shia, J.; et al. Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer. Ann. Surg. Oncol. 2017, 24, 2482–2490, doi:10.1245/s10434-017-5896-1.
  48. Song, S.; Li, Z.; Niu, L.; Zhou, X.; Wang, G.; Gao, Y.; Wang, J.; Liu, F.; Sui, Q.; Jiao, L.; et al. Hypervascular hepatic focal lesions on dynamic contrast-enhanced CT: Preliminary data from arterial phase scans texture analysis for classification. Clin. Radiol. 2019, 74, 653.e11–653.e18, doi:10.1016/j.crad.2019.05.010.
  49. Trebeschi, S.; Drago, S.; Birkbak, N.; Kurilova, I.; Cǎlin, A.; Pizzi, A.D.; Lalezari, F.; Lambregts, D.; Rohaan, M.; Parmar, C.; et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann. Oncol. 2019, 30, 998–1004, doi:10.1093/annonc/mdz108.
  50. Velichko, Y.S.; Mozafarykhamseh, A.; Trabzonlu, T.A.; Zhang, Z.; Rademaker, A.W.; Yaghmai, V. Association Between the Size and 3D CT-Based Radiomic Features of Breast Cancer Hepatic Metastasis. Acad. Radiol. 2020, doi:10.1016/j.acra.2020.03.004.
  51. Gatos, I.; Tsantis, S.; Karamesini, M.; Spiliopoulos, S.; Karnabatidis, D.; Hazle, J.D.; Kagadis, G.C. Focal liver lesions segmentation and classification in nonenhanced T2-weighted MRI. Med. Phys. 2017, 44, 3695–3705, doi:10.1002/mp.12291.
  52. Jansen, M.J.A.; Kuijf, H.J.; Veldhuis, W.B.; Wessels, F.J.; Viergever, M.A.; Pluim, J.P.W. Automatic classification of focal liver lesions based on MRI and risk factors. PLoS ONE 2019, 14, e0217053, doi:10.1371/journal.pone.0217053.
  53. Li, Z.; Mao, Y.; Huang, W.; Li, H.; Zhu, J.; Li, W.; Li, B. Texture-based classification of different single liver lesion based on SPAIR T2W MRI images. BMC Med. Imaging 2017, 17, 42, doi:10.1186/s12880-017-0212-x.
  54. Liang, H.-Y.; Huang, Y.-Q.; Yang, Z.-X.; Ding, Y.-; Zeng, M.-S.; Rao, S.-X. Potential of MR histogram analyses for prediction of response to chemotherapy in patients with colorectal hepatic metastases. Eur. Radiol. 2016, 26, 2009–2018, doi:10.1007/s00330-015-4043-2.
  55. Reimer, R.P.; Reimer, P.; Mahnken, A.H. Assessment of Therapy Response to Transarterial Radioembolization for Liver Metastases by Means of Post-treatment MRI-Based Texture Analysis. Cardiovasc. Interv. Radiol. 2018, 41, 1545–1556, doi:10.1007/s00270-018-2004-2.
  56. Zhang, H.; Li, W.; Hu, F.; Sun, Y.; Hu, T.; Tong, T. MR texture analysis: Potential imaging biomarker for predicting the chemotherapeutic response of patients with colorectal liver metastases. Abdom. Radiol. 2019, 44, 65–71, doi:10.1007/s00261-018-1682-1.
  57. Chatterjee, A.; Vallieres, M.; Dohan, A.; Levesque, I.R.; Ueno, Y.; Bist, V.; Saif, S.; Reinhold, C.; Seuntjens, J. An Empirical Approach for Avoiding False Discoveries When Applying High-Dimensional Radiomics to Small Datasets. IEEE Trans. Radiat. Plasma Med. Sci. 2018, 3, 201–209, doi:10.1109/TRPMS.2018.2880617.
  58. Peerlings, J.; Woodruff, H.C.; Winfield, J.M.; Ibrahim, A.; Van Beers, B.E.; Heerschap, A.; Jackson, A.; Wildberger, J.E.; Mottaghy, F.M.; DeSouza, N.M.; et al. Stability of radiomics features in apparent diffusion coefficient maps from a multi-centre test-retest trial. Sci. Rep. 2019, 9, 4800, doi:10.1038/s41598-019-41344-5.
  59. Rahmim, A.; Bak-Fredslund, K.P.; Ashrafinia, S.; Lu, L.; Schmidtlein, C.R.; Subramaniam, R.M.; Morsing, A.; Keiding, S.; Horsager, J.; Munk, O.L. Prognostic modeling for patients with colorectal liver metastases incorporating FDG PET radiomic features. Eur. J. Radiol. 2019, 113, 101–109, doi:10.1016/j.ejrad.2019.02.006.
  60. Wagner, F.; Hakami, Y.A.; Warnock, G.; Fischer, G.; Veit-Haibach, P.; Huellner, M. Comparison of Contrast-Enhanced CT and [(18)F]FDG PET/CT Analysis Using Kurtosis and Skewness in Patients with Primary Colorectal Cancer. Mol. Imaging Biol. 2017, 19, 795–803, doi:10.1007/s11307-017-1066-x.
  61. Van Helden, E.J.; Vacher, Y.J.L.; Van Wieringen, W.N.; Van Velden, F.H.P.; Verheul, H.M.W.; Hoekstra, O.S.; Boellaard, R.; Oordt, C.W.M.-V.D.H.V. Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 2307–2317, doi:10.1007/s00259-018-4100-6.
  62. Shur, J.; Orton, M.; Connor, A.; Fischer, S.; Moulton, C.; Gallinger, S.; Koh, D.; Jhaveri, K.S. A clinical‐radiomic model for improved prognostication of surgical candidates with colorectal liver metastases. J. Surg. Oncol. 2019, 121, 357–364, doi:10.1002/jso.25783.
  63. Weber, M.; Kessler, L.; Schaarschmidt, B.; Fendler, W.P.; Lahner, H.; Antoch, G.; Umutlu, L.; Herrmann, K.; Rischpler, C. Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. Nucl. Med. Commun. 2020, 41, 363–369, doi:10.1097/MNM.0000000000001150.
  64. Lambin, P.; Leijenaar, R.T.; Deist, T.M.; Peerlings, J.; De Jong, E.E.; Van Timmeren, J.; Sanduleanu, S.; LaRue, R.T.H.M.; Even, A.J.; Jochems, A.; et al. Radiomics: The bridge between medical imaging and personalized medicine. Nat. Rev. Clin. Oncol. 2017, 14, 749–762, doi:10.1038/nrclinonc.2017.141.
  65. Park, J.E.; Kim, D.; Kim, H.S.; Park, S.Y.; Kim, J.Y.; Cho, S.J.; Shin, J.H.; Kim, J.H. Quality of science and reporting of radiomics in oncologic studies: Room for improvement according to radiomics quality score and TRIPOD statement. Eur. Radiol. 2020, 30, 523–536, doi:10.1007/s00330-019-06360-z.
  66. Whiting, P.; Rutjes, A.W.; Westwood, M.E.; Mallett, S.; Deeks, J.J.; Reitsma, J.B.; Leeflang, M.M.; Sterne, J.A.; Bossuyt, P. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann. Intern. Med. 2011, 155, 529–536, doi:10.7326/0003-4819-155-8-201110180-00009.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Feedback